Stoke Therapeutics Inc (STOK) ニュース

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

– Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg...

Form 144 - Report of proposed sale of securities

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

– New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment...

Form 4 - Statement of changes in beneficial ownership of securities

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

– Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics –...